NasdaqCM:STML

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Stemline Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: STML's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.4%

STML

0.7%

US Biotechs

1.8%

US Market


1 Year Return

-20.5%

STML

22.1%

US Biotechs

3.7%

US Market

Return vs Industry: STML underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: STML underperformed the US Market which returned 3.7% over the past year.


Shareholder returns

STMLIndustryMarket
7 Day-1.4%0.7%1.8%
30 Day125.4%4.9%5.6%
90 Day88.9%10.7%-7.4%
1 Year-20.5%-20.5%23.3%22.1%6.1%3.7%
3 Year40.8%40.8%36.3%31.7%28.3%19.8%
5 Year-11.9%-11.9%-2.5%-8.3%52.4%35.1%

Price Volatility Vs. Market

How volatile is Stemline Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Stemline Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: STML ($11.9) is trading below our estimate of fair value ($35.54)

Significantly Below Fair Value: STML is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: STML is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: STML is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate STML's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: STML is overvalued based on its PB Ratio (3.9x) compared to the US Biotechs industry average (3.8x).


Next Steps

Future Growth

How is Stemline Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

55.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: STML is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: STML is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: STML is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: STML's revenue (34.8% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: STML's revenue (34.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if STML's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Stemline Therapeutics performed over the past 5 years?

-22.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: STML is currently unprofitable.

Growing Profit Margin: STML is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: STML is unprofitable, and losses have increased over the past 5 years at a rate of -22.6% per year.

Accelerating Growth: Unable to compare STML's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: STML is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: STML has a negative Return on Equity (-47.89%), as it is currently unprofitable.


Next Steps

Financial Health

How is Stemline Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: STML's short term assets ($169.1M) exceed its short term liabilities ($22.8M).

Long Term Liabilities: STML's short term assets ($169.1M) exceed its long term liabilities ($206.5K).


Debt to Equity History and Analysis

Debt Level: STML is debt free.

Reducing Debt: STML had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: STML has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if STML has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Stemline Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate STML's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate STML's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if STML's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if STML's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of STML's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure


CEO

Ivan Bergstein (53yo)

16.75yrs

Tenure

US$5,290,981

Compensation

Dr. Ivan Bergstein, M.D., founded Stemline Therapeutics, Inc. in August 2003 and has been its Chairman, Chief Executive Officer and President. Dr. Bergstein served as the Medical Director of Keryx Biopharm ...


CEO Compensation Analysis

Compensation vs Market: Ivan's total compensation ($USD5.29M) is above average for companies of similar size in the US market ($USD2.29M).

Compensation vs Earnings: Ivan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ivan Bergstein
Founder16.75yrsUS$5.29m5.82% $33.4m
David Gionco
Senior VP of Finance & Chief Accounting Officer6.33yrsUS$1.40m0.68% $3.9m
Kenneth Hoberman
COO & Corporate Secretary8.33yrsUS$2.46m1.61% $9.2m
Robert Francomano
Chief Commercial Officerno dataUS$2.07m0.41% $2.4m
John Salvagno
Senior Vice President of Quality & Operationsno datano datano data

8.3yrs

Average Tenure

53.5yo

Average Age

Experienced Management: STML's management team is seasoned and experienced (8.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ivan Bergstein
Founder16.75yrsUS$5.29m5.82% $33.4m
Kenneth Zuerblis
Independent Director8.17yrsUS$281.05k0.12% $715.4k
Alan Forman
Independent Director5.08yrsUS$282.30k0.18% $1.1m
Ron Bentsur
Independent Director11.33yrsUS$428.00k0.14% $778.8k
Hagop Kantarjian
Member of the Scientific Advisory Boardno datano datano data
Owen O'Connor
Member of the Scientific Advisory Boardno datano datano data
Patrick Wen
Member of the Scientific Advisory Boardno datano datano data
Darren Cline
Independent Director2.08yrsUS$269.80k0.074% $422.1k
David Reardon
Member of the Scientific Advisory Boardno datano datano data
Daniel Hume
Independent Director2.08yrsUS$271.05k0.074% $422.1k

6.6yrs

Average Tenure

53yo

Average Age

Experienced Board: STML's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: STML insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.1%.


Top Shareholders

Company Information

Stemline Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stemline Therapeutics, Inc.
  • Ticker: STML
  • Exchange: NasdaqCM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$572.955m
  • Shares outstanding: 48.15m
  • Website: https://www.stemline.com

Number of Employees


Location

  • Stemline Therapeutics, Inc.
  • 750 Lexington Avenue
  • Eleventh Floor
  • New York
  • New York
  • 10022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STMLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2013
S46DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2013

Biography

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and Europe. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 04:31
End of Day Share Price2020/05/22 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.